SWTUY News and Press, Swedish Orphan Bio S/Adr

In March, Sanofi (NASDAQ: SNY) and its Sweden-based partner Sobi (OTC: SWTUY) announced positive phase 3 clinical trial results for efanesoctocog alfa, their jointly developed drug candidate for severe hemophilia A. The two companies expect to begin submitting applicatio...

Shares of drugmaker Dova Pharmaceuticals (NASDAQ: DOVA) rose by 86.5% in September, according to data provided by S&P Global Market Intelligence . This added to Dova's big gains in 2019, piggybacking on a June jump of 59.9%. Year to date, the company's shares have skyrocketed 271.2%. A...

Shares of Dova Pharmaceuticals (NASDAQ: DOVA) , a biopharmaceutical company focused on rare blood-based diseases, leapt higher following a generous buyout offer. The European rare-disease drugmaker  Sobi (OTC: SWTUY) will acquire Dova for up to $29 per share, which is around 45% ...

NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Swedish Orphan Biovitrum AB (OTCPINK: SWTUY ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 17, 2019 at 9:00 AM Eastern Time. To listen to the event live or access a replay of the call - visit...

STOCKHOLM , March 25, 2019 /PRNewswire/ -- Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders (NORD) for the 2019 Rare Impact Awards. The companies were nominated in the category of Industry Innovation in recognition of the U...

STOCKHOLM , Feb. 26, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI)   and Novimmune SA announced the presentation of   late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH...

STOCKHOLM , Feb. 21, 2019 /PRNewswire/ -- Save the date for Swedish Orphan Biovitrum AB (publ) (Sobi™) Capital Markets Day on 14 May 2019 . The event will take place at Karolinska Institutet Biomedicum, Solnavägen 9, Solna, from 12:30 – 16:30. A lighter lunch will be...

STOCKHOLM , Feb. 11, 2019 /PRNewswire/ -- On 20 February, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial analysts and media are invited to participate in a telephone conference, which will in...

STOCKHOLM , Feb. 7, 2019 /PRNewswire/ -- Sobi™ will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic , 6-8 February 2019 , showing evidence on the safety, efficacy and long-term benefits of its extended ha...

STOCKHOLM , Jan. 24, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future...